August 29, 2016 4:53 AM ET

Healthcare Equipment and Supplies

Company Overview of EndoGastric Solutions, Inc.

Company Overview

EndoGastric Solutions, Inc., a medical device company, develops, markets, and sells natural orifice surgical products and procedures to advance the treatment of gastrointestinal diseases. It offers EsophyX, a technology that enables transoral reconstructive surgery; SerosaFuse Fasteners, a non-resorbable polypropylene material product that have equivalent web strength to a 3.0 suture; trainer-led courses for surgeons; and consultative, support, pre-authorization, internal appeal, and external medical review services. The company was formerly known as EsophyX, Inc. and changed its name to EndoGastric Solutions, Inc. in 2005. EndoGastric Solutions, Inc. was founded in 2002 and is headquartered...

1900 O'Farrell Street

Suite 325

San Mateo, CA 94403

United States

Founded in 2002

Phone:

650-578-5100

Fax:

650-578-5101

Key Executives for EndoGastric Solutions, Inc.

Chief Executive Officer, President and Director
Age: 55
Chief Financial Officer
Age: 58
Director of Finance and Controller
Senior Director of US Sales
Compensation as of Fiscal Year 2016.

EndoGastric Solutions, Inc. Key Developments

FDA Clears EndoGastric Solutions’ EsophyX® Device

EndoGastric Solutions announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the EsophyX® Z device. Designed for compatibility with the company’s existing 7.5 mm SerosaFuse® Implantable Fastener cartridges, EsophyX Z allows physicians to reconstruct the gastroesophageal valve and then secure tissue with a trigger-like handle, making the device similar to stapler like devices often utilized in surgery. EsophyX Z will enter a limited release in the U.S. before full commercialization during the summer. Additionally, it is being used in the American Gastroenterological Association’s STAR Registry, which will provide the first real-world data comparing patient outcomes after traditional laparoscopic surgery and TIF with the EsophyX® device.

EndoGastric Solutions Announces Presentation of Three-Year Follow-Up Data from TEMPO

EndoGastric Solutions announced the presentation of three-year follow-up data from TEMPO, a prospective, randomized, multicenter clinical study. The data confirms long-term control of chronic GERD after a Transoral Incisionless Fundoplication (TIF®) procedure with the EsophyX® device. The study will be presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2016 Annual meeting, taking place from March 16-19, 2016 in Boston, Massachusetts. Sixty-three patients who suffered from troublesome chronic GERD symptoms were randomized to either undergo the TIF procedure (n=40) using the EsophyX device or take proton pump inhibitor (PPI) therapy (n=23); all patients in PPI control group crossed over and received TIF procedures six months after the start of the study. At up to 36 months follow-up, 91% of patients reported elimination of troublesome regurgitation, 70% were able to completely stop PPI therapy, and reflux esophagitis healed in 87% of patients. The data will be presented the SS08 Flexible Endoscopy session starting at 3:30 PM to 5:30 PM on March 17, 2016 in Ballroom A moderated by Frederick L. Greene, MD and G. V. Rao, MS, MAMS.

EndoGastric Solutions Secures $50 Million in Financing

EndoGastric Solutions announced that it has secured additional new financing of up to $50.0 million, led by CRG (formerly Capital Royalty L.P.) and existing EGS investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, Foundation Medical Partners, and Radius Ventures. EGS plans to use proceeds from the financing to begin broad-scale commercialization, as well as making further R&D investments in next generation products used in their TIF procedure.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EndoGastric Solutions, Inc., please visit www.endogastricsolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.